Jay Bowman-Kirigin

  • Salt Lake City, UT

  • Westminster College-Salt Lake City (2011)

  • Immunology

  • Gavin P. Dunn, M.D., Ph.D.

  • Antigen presentation in central nervous system antitumor immunity

  • bowman-kiriginj@wustl.edu


Glioblastoma (GBM) patients face a paucity of treatment options and universally have poor outcomes. With treatment, the median survival is 15-20 months. Moreover, the standard of care remains the same since 2005, and there are no FDA approved immune therapies. Among the factors that may contribute to this: the anti-tumor immune response to brain tumors is poorly understood.  Which components of the innate immune response are indispensable for the immune response to glioblastoma? How does the T cell response endogenously arise against brain tumors? And finally, how does lymphatic drainage and antigen presentation work for brain tumors. My project focused on using pre-clinical mouse models to understand how the immune system sees and responds to brain tumors, with the particular goal of defining the function of conventional dendritic cell 1 subset in the context of central nervous system anti-tumor immunity. I established that this cell type was critical in mounting anti-tumor immune responses in the brain, and I filled in some of the steps of how this particular cell subset performs this function. I also extended my findings to humans and performed experiments which established evidence that antigen presentation happens in human glioblastoma. The hope is that understanding of how the endogenous immune response evolves against brain tumors will unlock the keys to developing more effective immune therapies for GBM.

Graduate Publications:

Fu Y, Liu CJ, Kobayashi DK, Johanns TM, Bowman-Kirigin JA, Schaettler MO, Mao DD, Bender D, Kelley DG, Uppaluri R, Bi WL, Dunn IF, Tao Y, Luo J, Kim AH, Dunn GP. 2020 GATA2 Regulates Constitutive PD-L1 and PD-L2 Expression in Brain Tumors. Sci Rep, 10(1):9027.

Liu CJ, Schaettler M, Blaha DT, Bowman-Kirigin JA, Kobayashi DK, Livingstone AJ, Bender D, Miller CA, Kranz DM, Johanns TM, Dunn GP. 2020 Treatment of an aggressive orthotopic murine glioblastoma model with combination checkpoint blockade and a multivalent neoantigen vaccine.. Neuro Oncol, 22(9):1276-1288.

Johanns TM, Bowman-Kirigin JA, Liu C, Dunn GP. 2017 Targeting Neoantigens in Glioblastoma: An Overview of Cancer Immunogenomics and Translational Implications. Neurosurgery, 64(CN_suppl_1):165-176.

Last Updated: 9/19/2019 10:06:44 PM

Back to top